Zobrazeno 1 - 10
of 493
pro vyhledávání: '"Ken H Young"'
Autor:
Praveen Neeli, Perry Ayn Mayson A. Maza, Dafei Chai, Dan Zhao, Xen Ping Hoi, Keith Syson Chan, Ken H. Young, Yong Li
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Multiple myeloma (MM), a hematological malignancy of the bone marrow, remains largely incurable. The orphan G protein-coupled receptor, GPRC5D, which is uniquely expressed in plasma cells and highly expressed in MM, is a compelling candidate
Externí odkaz:
https://doaj.org/article/2a29d458e1ab4ff8b1f12beabb5f483d
Autor:
Zijun Y. Xu-Monette, Cancan Luo, Li Yu, Yong Li, Govind Bhagat, Alexandar Tzankov, Carlo Visco, Xiangshan Fan, Karen Dybkaer, Ali Sakhdari, Nicholas T. Wang, Alyssa F. Yuan, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Anamarija M. Perry, Wenting Song, Dennis O’Malley, Qingyan Au, Harry Nunns, Heounjeong Go, Michael B. Møller, Benjamin M. Parsons, Santiago Montes-Moreno, Maurilio Ponzoni, Andrés J.M. Ferreri, Aliyah R. Sohani, Jeremy S. Abramson, Bing Xu, Ken H. Young
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Deficient (d) DNA mismatch repair (MMR) is a biomarker predictive of better response to PD-1 blockade immunotherapy in solid tumors. dMMR can be caused by mutations in MMR genes or by protein inactivation, which can be detected by sequencing and immu
Externí odkaz:
https://doaj.org/article/5de2138da31648e09e4ad55f932a3cf2
Autor:
Steffen Falgreen, Anders Ellern Bilgrau, Rasmus Froberg Brøndum, Lasse Hjort Jakobsen, Jonas Have, Kasper Lindblad Nielsen, Tarec Christoffer El-Galaly, Julie Støve Bødker, Alexander Schmitz, Ken H Young, Hans Erik Johnsen, Karen Dybkær, Martin Bøgsted
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163711 (2016)
BACKGROUND:Dozens of omics based cancer classification systems have been introduced with prognostic, diagnostic, and predictive capabilities. However, they often employ complex algorithms and are only applicable on whole cohorts of patients, making t
Externí odkaz:
https://doaj.org/article/8337afb6a5084bed981a2871a326875a
Autor:
Dafei Chai, Junhao Wang, Chunmei Fan, Jing-Ming Lim, Xu Wang, Praveen Neeli, Xinfang Yu, Ken H. Young, Yong Li
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-23 (2024)
Abstract Background p53, the most frequently mutated gene in cancer, lacks effective targeted drugs. Methods We developed monoclonal antibodies (mAbs) that target a p53 hotspot mutation E285K without cross-reactivity with wild-type p53. They were del
Externí odkaz:
https://doaj.org/article/c893d2f686c94ed580b6f8dd6e662166
Autor:
Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H. Young, Xudong Zhang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Lymphoma is a highly heterogeneous lymphohematopoietic tumor. As our understanding of the biological and pathological characteristics of lymphoma improves, we are identifying an increasing number of lymphoma subtypes. Genotyping has enhanced our abil
Externí odkaz:
https://doaj.org/article/eee6ffc25d7a4bd2ac22c94afb1df9e0
Autor:
Zhaoxia Li, Wei Guo, Yangzhi Zhao, Haotian Wang, Jing Guo, Zhe Li, Bowen Wang, Luming Cao, Jihong Xu, Ken H. Young, Ou Bai
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Objective Recent studies have found a high prevalence of hepatitis B virus (HBV) infection in patients with non‐Hodgkin's lymphoma (NHL), especially B‐cell non‐Hodgkin's lymphoma (B‐NHL). However, most studies did not classify it and
Externí odkaz:
https://doaj.org/article/7f1e298d4ee1410bb284d225dab6b355
Publikováno v:
Cell Death and Disease, Vol 14, Iss 11, Pp 1-14 (2023)
Abstract Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies ne
Externí odkaz:
https://doaj.org/article/4a1b5059c45c4c00a198b50e43a2681c
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-38 (2023)
Abstract Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refra
Externí odkaz:
https://doaj.org/article/f2c986b61bc741d4abff3b0064c985a1
Autor:
Tiantian Yu, Zijun Y. Xu-Monette, Anand Lagoo, Wen Shuai, Bangchen Wang, Jadee Neff, Luis F. Carrillo, Eric D. Carlsen, Sergio Pina-Oviedo, Ken H. Young
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionOur previous studies have demonstrated that tumor-infiltrating lymphocytes (TILs), including normal B cells, T cells, and natural killer (NK) cells, in diffuse large B-cell lymphoma (DLBCL) have a significantly favorable impact on the cli
Externí odkaz:
https://doaj.org/article/68d6d3bcfc1a4a6291308b1158b27404
Autor:
Zhumei Zhan, Wei Guo, Xin Wan, Bowen Wang, Jia Li, Haotian Wang, Zhe Li, Yuhua Huang, Ken H. Young, Ou Bai
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveThe development of diffuse large B-cell lymphoma (DLBCL) is closely related to the host infection status. China is a highly endemic area for hepatitis B virus (HBV) infection. It is not clear whether HBV infection has a consistent effect on
Externí odkaz:
https://doaj.org/article/7164c0eb53a346a0a9902330d2797284